These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17561399)

  • 1. Cancer-specific mutations in phosphatidylinositol 3-kinase.
    Vogt PK; Kang S; Elsliger MA; Gymnopoulos M
    Trends Biochem Sci; 2007 Jul; 32(7):342-9. PubMed ID: 17561399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical and biological characterization of tumor-associated mutations of p110alpha.
    Denley A; Gymnopoulos M; Hart JR; Jiang H; Zhao L; Vogt PK
    Methods Enzymol; 2008; 438():291-305. PubMed ID: 18413256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
    Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoinositide 3-kinase: from viral oncoprotein to drug target.
    Vogt PK; Bader AG; Kang S
    Virology; 2006 Jan; 344(1):131-8. PubMed ID: 16364744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of the p110 alpha isoform of PI3K in early development of mouse embryos.
    Xu XY; Zhang Z; Su WH; Zhang Y; Feng C; Zhao HM; Zong ZH; Cui C; Yu BZ
    Mol Reprod Dev; 2009 Apr; 76(4):389-98. PubMed ID: 18932194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
    Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
    Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
    Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
    Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
    Garcia-Echeverria C; Sellers WR
    Oncogene; 2008 Sep; 27(41):5511-26. PubMed ID: 18794885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic PI3K deregulates transcription and translation.
    Bader AG; Kang S; Zhao L; Vogt PK
    Nat Rev Cancer; 2005 Dec; 5(12):921-9. PubMed ID: 16341083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo functional analysis of the counterbalance of hyperactive phosphatidylinositol 3-kinase p110 catalytic oncoproteins by the tumor suppressor PTEN.
    Andrés-Pons A; Rodríguez-Escudero I; Gil A; Blanco A; Vega A; Molina M; Pulido R; Cid VJ
    Cancer Res; 2007 Oct; 67(20):9731-9. PubMed ID: 17942903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA gene mutations in breast carcinoma in Malaysian patients.
    Ching-Shian Leong V; Jabal MF; Leong PP; Abdullah MA; Gul YA; Seow HF
    Cancer Genet Cytogenet; 2008 Dec; 187(2):74-9. PubMed ID: 19027487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.
    Hoeflich KP; O'Brien C; Boyd Z; Cavet G; Guerrero S; Jung K; Januario T; Savage H; Punnoose E; Truong T; Zhou W; Berry L; Murray L; Amler L; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2009 Jul; 15(14):4649-64. PubMed ID: 19567590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oncogenic p110alpha subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase.
    Carson JD; Van Aller G; Lehr R; Sinnamon RH; Kirkpatrick RB; Auger KR; Dhanak D; Copeland RA; Gontarek RR; Tummino PJ; Luo L
    Biochem J; 2008 Jan; 409(2):519-24. PubMed ID: 17877460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.
    Calleros L; Sánchez-Hernández I; Baquero P; Toro MJ; Chiloeches A
    Carcinogenesis; 2009 Oct; 30(10):1670-7. PubMed ID: 19700418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in the inter-SH2 domain of the regulatory subunit of phosphoinositide 3-kinase: effects on catalytic subunit binding and holoenzyme function.
    Elis W; Lessmann E; Oelgeschlager M; Huber M
    Biol Chem; 2006 Dec; 387(12):1567-73. PubMed ID: 17132102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
    Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
    Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population.
    Abubaker J; Bavi P; Al-Harbi S; Ibrahim M; Siraj AK; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    Oncogene; 2008 Jun; 27(25):3539-45. PubMed ID: 18193083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new evaluation method for quantifying PI3K activity by HTRF assay.
    Sugita H; Dan S; Kong D; Tomida A; Yamori T
    Biochem Biophys Res Commun; 2008 Dec; 377(3):941-5. PubMed ID: 18952065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of class IA PI3Ks.
    Wu H; Yan Y; Backer JM
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):242-4. PubMed ID: 17371249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new mutational AKTivation in the PI3K pathway.
    Brugge J; Hung MC; Mills GB
    Cancer Cell; 2007 Aug; 12(2):104-7. PubMed ID: 17692802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.